The research report from china merchants points out that high-end product sales are weak, and imeik technology development (300896.SZ) will face short-term pressure on performance in Q3 2024. The company's performance continues to grow steadily, product structure has been adjusted, and the HiTi product continues its stable growth; the company’s medical instruments containing cross-linked sodium hyaluronate gel with polyethylene glycol microspheres have obtained medical instrument registration certificates, suitable for injection filling in the upper layer of adult membrane to improve mild to moderate chin retrusion, which is expected to become a new performance growth point for the company. The company continues to advance product research and development to enhance market competitiveness. Considering the current consumer weakness and the changes in the company's income structure, it is expected that the company's net income attributable to the parent for 2024-2026 will be 2.156/2.559/3.031 billion yuan, with year-on-year growth of 16%/19%/18%, corresponding to PEs of 30.3/25.5/21.6 times, maintaining a "shareholding" rating.